Mandate

Vinge advises HealthCap in conjunction with its investment in Elsa Science

November 05, 2021 M&A

Vinge has advised HealthCap in conjunction with its investment in Elsa Science, which develops an app that provides patients suffering from rheumatoid arthritis to receive tailormade treatment.

The financing round is headed by Healthcap and also existing investors such as the Finnish venture capital company Inventure, Crowberry Capital from Iceland, Norrsken VC as well as Noaber from the Netherlands.

Vinge’s team primarily consisted of Johan Winnerblad, Stina Bengtsson, Hannah Kajlinger and Lisa Hörnqvist.

Related

Vinge advises Röko AB (publ) in connection with the establishment of its MTN programme

Vinge has advised Röko AB (publ) ("Röko") on the establishment of a medium-term note programme (the "MTN Programme") with a framework amount of SEK 5 billion.
November 13, 2026

Vinge advises Telavox on the sale of its Nordic customer base to Telia

Vinge has advised Telavox AB (“Telavox”) on the sale of Telavox’s Nordic customer base for business services to Telia Company AB (“Telia”). The customer base comprises approximately 24,000 business customers and 325,000 end users in Sweden, Denmark, Finland, and Norway. The purchase price amounts to SEK 3.8 billion plus a potential additional earn-out.
November 13, 2026

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026